aavantgarde_logo.jpg
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
May 03, 2024 03:00 ET | AAVantgarde Bio
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
AAVANTAGARDE BIO LOGO_low_res.jpg
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
June 06, 2023 08:00 ET | AAVantgarde Bio
- Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...
nacuity-pharmaceuticals-inc.jpg
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
May 31, 2023 09:00 ET | Nacuity Pharmaceuticals, Inc.
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH Interim efficacy data anticipated by year end 2023 FORT WORTH, Texas, May 31, 2023 (GLOBE...
logo_ProQR-150x150.png
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 16, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 24, 2021 07:00 ET | ProQR Therapeutics N.V.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)QR-421a observed to be well...
logo_ProQR-150x150.png
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
March 17, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
February 16, 2021 16:30 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Conference Call Series
June 12, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 31, 2020 06:00 ET | ProQR Therapeutics N.V.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...
logo_ProQR-150x150.png
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 25, 2020 16:15 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...